secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001599298-25-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit: Ivonescimab gets second NMPA approval in China; OS hazard ratio 0.777
-----------------------------------------------------------------------------

- NMPA approved ivonescimab for front-line PD-L1+ advanced NSCLC based on HARMONi-2 Phase III trial.
- Interim OS analysis showed hazard ratio 0.777 (22% reduction in risk of death) at 39% data maturity.
- Primary endpoint PFS previously showed HR 0.51 (p<0.0001) favoring ivonescimab over pembrolizumab.
- Summit is enrolling HARMONi-7, a multiregional Phase III trial of ivonescimab vs pembrolizumab in same population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/0001599298-25-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/smmt-20250425.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer